AP82 schreef op 21 januari 2026 16:38:
First Berlin Equity Research has published an updated report on Pharming Group NV, reiterating its Buy recommendation and raising the 12-month price target from €2.40 to €2.60. Analyst Simon Scholes highlights Pharming's stronger-than-expected preliminary 2025 revenues, which rose approximately 27% to $376 million, surpassing the upper end of company guidance. The report also notes upcoming clinical read-outs for leniolisib in two potential blockbuster indications and the pivotal phase 2 study of KL1333, reinforcing a positive outlook for the company.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: rc_24490), on January 21, 2026, and is solely responsible for the information contained therein.
(C) Copyright 2026 - Public Technologies (PUBT)